 Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells

Katerina V. Gurova, Oskar W. Rokhlin, Andrei V. Budanov, Ludmila G. Burdelya, Peter M. Chumakov, Michael B. Cohen, and Andrei V. Gudkov

Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195 [K. V. G., A. V. B., L. G. B., P. M. C., A. V. G.], and Department of Pathology, University of Iowa, Iowa City, Iowa 52242 [O. W. R., M. B. C.]

ABSTRACT

Both inactivation of p53 function and loss of sensitivity to Fas contribute to a malignant phenotype and frequently occur during tumor progression. Although in the majority of cases only one of the p53 alleles is mutated, some tumors acquire mutations in both alleles of the p53 gene. To determine the biological significance of this phenomenon, we analyzed p53 mutants, p53223Leu and p53274Pro, from Fas-resistant prostate carcinoma cell line DU145. Both mutants differed from wild-type p53 in their conformation, transactivation ability, and effect on the growth of p53-deficient cells, with p53223Leu being more similar to wild-type p53 than was p53274Pro. Interestingly, the biological effect of coexpression of the DU145-derived mutants was dramatically different from that of each mutant expressed alone. Whereas neither of the two mutants was found to be dominant-negative against wild-type p53, each neutralized the other’s growth-suppressive effects and, in combination, were capable of down-regulating Fas expression and converting Fas-sensitive prostate carcinoma cells PC3 into Fas-resistant ones. These results indicate that two different p53 mutants that are separately rather weak can cooperate to generate p53 protein with anti-Fas function that is likely to provide additional selective advantages to the tumor.

INTRODUCTION

Of more than 10,000 different human tumors analyzed to date, 45–50% contained inactivating mutations within the p53 gene (1) making it the most frequently mutated gene in cancer. Frequencies of mutations vary from one tumor type to another (2) ranging from 60–65% of lung and colon cancers, 40–45% of stomach, esophagus, and bladder cancers, 25–30% of breast, liver, and prostate cancers and of lymphomas, and of 10–15% of leukemias (1). Interestingly, the nature of mutations acquired by p53 in the tumors clearly differentiates this gene from other tumor suppressors that are inactivated predominantly by deletions or transcriptional silencing, resulting in the lack of functional protein. On the contrary, 80–85% of tumor-derived alterations in the p53 gene are missense point mutations localized within the DNA-binding domain of the protein (1–4). Such mutations result in the accumulation of large amounts of abnormally stable p53 protein that loses specific DNA-binding and transactivation functions. The fact that tumor-derived mutations in p53 preserve expression of full-length, although altered, proteins suggests that mutant p53 could provide some selective advantages for tumor cells. One such property is the dominant-negative activity of some of the tumor-derived p53 mutants capable of suppressing function of the wild-type allele.

Nevertheless, the wild-type alleles of p53 are frequently lost during further tumor progression, indicating that the dominant-negative effect of p53 mutants is insufficient for complete inactivation of the wild-type function and that they might have some additional properties contributing to cancer development. In fact, some of the p53 mutants exhibit gain-of-function and can modulate tumor cell phenotype, even in the absence of the wild-type allele, by increasing clonogenic potential, tumorigenicity, and invasiveness (5–8). In addition, some p53 mutants are capable of (a) further increasing genetic instability by abrogating the mitotic spindle checkpoint (9); (b) changing differentiation status of cells (10); and (c) increasing resistance to certain chemotherapeutic drugs (11–13).

The majority among p53 mutant tumors express a single mutant allele of p53 (see p53 mutation database). However, p53 mutation databases contain several cases in which two different p53 mutations are coexpressed in one tumor, presumably resulting in the formation of mixed proteins built from all possible combinations of mutant p53 monomers. The biological significance of coexpression of two different mutants in one tumor has not been analyzed and became the subject of the present work.

As a model, we chose prostate carcinoma cell line DU145, which carries different mutations in two alleles of p53 (14) none of which has been characterized before. To understand the biological sense of their coexistence in one tumor, we analyzed the functionality of these mutants. Our approach was to introduce them into p53-deficient cells of prostate and nonprostate origin and to determine phenotypic changes associated with their separate or combined expression. We found that the properties of the p53 protein complex resulting from the coexpression in one cell of two DU145 mutants was different from what could be expected from a simple sum of the properties of two mutants. One of the most remarkable new functions of the new p53 was its ability to confer resistance to Fas-mediated apoptosis, a new gain-of-function activity that presumably reflects the potential mechanism behind the selection of this combination of p53 mutants within a tumor.

MATERIALS AND METHODS

Plasmids. The plasmids used in this study are described in Table 1. Cell Culture. We used the following cell lines: DU145 and PC3 (both of which are human prostate carcinoma-derived); Saos-2 (human osteosarcoma); AmphiPack-293 (A293-derived packaging cell line; Clontech); 10(1) (BALB/c-derived fibroblast cell line; kindly provided by Arnold Levine); and C8 (E1a + ras-transformed mouse embryo fibroblasts; a gift from Scott Lowe, Cold Spring Harbor Laboratory). Prostate carcinoma cell lines were maintained in RPMI 1640 (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Hyclone Laboratories), 4 mM l-glutamine, 1 mM sodium pyruvate, 1 mM HEPES, and 0.1 mM 2-mercaptoethanol. C8 cells were maintained in DMEM (Life Technologies, Inc.) with 10% fetal bovine serum; and Saos-2, 10(1), and AmphiPack-293 cells were cultured in the same medium, but supplemented with 10% of FetalClone (Hyclone Laboratories). All of the media contained 100 units/ml penicillin and 100 μg/ml streptomycin.

Transfection and Retroviral Transduction. Packaging cells plated in 60-mm plates were transfected with 10 μg of retroviral vector DNA using standard calcium phosphate procedure. The medium was changed after 8 h. Virus-containing media supplied with 8 μg/ml of Polybrene (Sigma) were collected at 24 and 48 h posttransfection and were used for infection. Virus-

Received 11/25/02; accepted 3/31/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grants CA75179 and CA60730 (to A. V. G.) and CA76673 (to M. B. C.).
2 K. V. G. and O. W. R. contributed equally to the work and are listed alphabetically.
3 To whom requests for reprints should be addressed, at Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: (216) 445-1205; Fax: (216) 444-0512; E-mail: gudkov@ccf.org.

transduced cells were selected for the resistance to an appropriate selective agent (G418, hygromycin, or puromycin, depending on the vector) up to a complete death of noninfected cells. Transfections of other cells were carried out with LipofectAMINE Plus reagent (Life Technologies, Inc.) according to the manufacturer’s recommendations.

**Isolation and Cloning of Mutant p53 from DU145 Cells.** cDNA was synthesized from total RNA of DU145 cells using SuperScript II (Life Technologies, Inc.) reverse transcriptase from oligo(dT) primers. Primers flanking the coding region of the human p53 gene (left, 5'-agcctgctttctggattgg; right, 5'-gagggagggaggagaga) were used for PCR amplification with synthesized cDNA as a template. The PCR product of 1287 bp was cloned to pCR2.1 vector using TA Cloning kit (Invitrogen). Because it was known that DU145 cells contain different point mutations in each allele of the p53 gene (223 codon CCT to CTT in one, and codon 274 GTT to TTT in the other; Ref. 14), we screened resulting clones by hybridization with the mutant-specific 17-mer (5'-ggcaggggagggagaga) were used for PCR amplification with synthesized cDNA. cDNA was recloned in retroviral-expressing vectors with different selective markers; and pLPCX (Clontech) transgene expression was regulated by LTR5 and hygromycin resistance gene by SV40 promoter; and pLPC (Clontech) transgene expression was regulated by CMV and puromycin resistance gene by LTR.

**Colony, Cell Growth, and Apoptotic Assays.** For colony assay, subconfluent cultures in 60-mm plates were transfected or infected with the tested constructs and selected with an appropriate antibiotic (or combination of antibiotics in case of infection or transfection with two different vectors). In parallel, the same transfection solutions or virus-containing media were transferred on Rat1 cells, known to be resistant to transduction with wild-type p53, for estimation of transfection efficiency or virus titer. Cell growth after treatment with apoptosis-inducing agents was estimated by methylene blue staining, cells were lysed in radioimmunoprecipitation assay buffer [25 mM Tris–HCl (pH 7.2), 125 mM NaCl, 1% NP40, 1% sodium deoxycholate, and 1 mM EDTA] containing 1 mM phenylmethylsulfyl fluoride (Sigma), 10 μg/ml aprotinin (Sigma), 10 μg/ml leupeptin (Sigma), 10 mM sodium orthovanadate (Sigma), and 1 mM NaF (Sigma). Cell lysates were incubated 30 min on ice and centrifuged at 15,000 × g for 20 min. Then lysates were precleared for 1 h at 4°C with the mixture of nonspecific antibodies corresponding to the isotype of the primary antibodies together with protein A/G agarose (Santa Cruz Biotechnology). Ten μg of one of four antibodies (Pab 240 (Santa Cruz), Pab 1620 (Calbiochem), DO1 (Santa Cruz), and nonspecific mouse IgG mixture) were added to 0.5 ml of the lysate and incubated overnight at 4°C, after which 20 μl of protein A/G agarose (Santa Cruz) was added for 1 h. After washings in lysis buffer, agarose pellets were boiled in Laemmli sample buffer, used for Western immunoblotting (see below) and detected with biotinylated anti-p53 antibodies (Boehringer Mannheim) and streptavidin-conjugated horseradish peroxidase. For Western blotting, cells were lysed in radioimmunoprecipitation assay buffer [25 mM Tris HCl (pH 7.2), 125 mM NaCl, 1% NP40, 1% sodium deoxycholate, and 1 mM EDTA] containing 1 mM phenylmethylsulfyl fluoride (Sigma), 10 μg/ml aprotinin (Sigma), and 10 μg/ml of leupeptin (Sigma). Protein concentrations were determined with Bio-Rad DC protein assay kit. Equal protein amounts were run on gradient 4–20% precast gels (Novex) and blotted onto polyvinylidene difluoride membranes (Amersham). The following antibodies were used: anti-p53–monoclonal mouse DO1 (Santa Cruz) and biotinylated polyclonal rabbit (Boehringer Mannheim); anti-p21–polyclonal rabbit (Santa Cruz); anti-mdm2–monoclonal mouse (Santa Cruz); anti-CD95–monoclonal mouse (Transduction Laboratories); anti-actin–polyclonal goat (Santa Cruz). Horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz. Quantitation of the data were performed using Quantity One software from Bio-Rad.

**Transactivation Assay.** Cells in subconfluent cultures were transfected with a combination of the plasmids carrying wild-type p53 or p53 mutants with reporter construct containing reporter CAT DNA under the minimal thymidine kinase promoter and p53-binding sequence from the promoter of p21/Waf1 gene (19). A control CMV-LacZ vector expressing β-galactosidase from the CMV promoter was included in all transfections. Parental vector, pBasicCAT, lacking p53 consensus element, was used as a control in the assays. Forty-eight-h posttransfection cell extracts were prepared, normalized according to protein concentrations, and used for the determination of CAT and β-galactosidase (Promega) activities.

**RESULTS**

Effect of DU145-derived p53 Mutants on Growth of p53-deficient Cells Is Cell-­Type-dependent and Different from Wild-Type p53. The accumulation of p53 protein in response to DNA damage or other types of stress may result in the induction of growth

---

**Table 1 Properties of vectors used in the study**

<table>
<thead>
<tr>
<th>Construct</th>
<th>Inserts</th>
<th>Selectable marker</th>
<th>Promoter for insert expression</th>
<th>References (base vectors)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pLX-p53</td>
<td>Human wt p53</td>
<td>Puromycin</td>
<td>LTR</td>
<td>Modified pLXSN (Clontech) with neo substituted for puro</td>
</tr>
<tr>
<td>pLX-GSE56</td>
<td>GSE56</td>
<td></td>
<td>LTR</td>
<td></td>
</tr>
<tr>
<td>pSH-p53</td>
<td>Human wt p53</td>
<td>Hygromycin</td>
<td>LTR</td>
<td>(15)</td>
</tr>
<tr>
<td>pSH-p53-223</td>
<td>p53-22£&lt;sup&gt;1-20&lt;/sup&gt;</td>
<td>Hygromycin</td>
<td>LTR</td>
<td>(15)</td>
</tr>
<tr>
<td>pSH-p53-274</td>
<td>p53-27£&lt;sup&gt;4-9&lt;/sup&gt;</td>
<td>Hygromycin</td>
<td>LTR</td>
<td>(15)</td>
</tr>
<tr>
<td>pPC-255p53</td>
<td>Human wt p53</td>
<td>Puromycin</td>
<td>CMV</td>
<td>Clontech</td>
</tr>
<tr>
<td>pPC-p53-223</td>
<td>p53-22£&lt;sup&gt;4-9&lt;/sup&gt;</td>
<td>Puromycin</td>
<td>CMV</td>
<td>Clontech</td>
</tr>
<tr>
<td>pPC-p53-274</td>
<td>p53-27£&lt;sup&gt;4-9&lt;/sup&gt;</td>
<td>Puromycin</td>
<td>CMV</td>
<td>Clontech</td>
</tr>
<tr>
<td>pcDNA3</td>
<td>Wild-type p53</td>
<td>G418</td>
<td>CMV</td>
<td>Invitrogen</td>
</tr>
<tr>
<td>p21-CAT</td>
<td>CAT</td>
<td>No</td>
<td>CMV</td>
<td>Stratagene</td>
</tr>
<tr>
<td>pCMV-β-gal</td>
<td>β-Galactosidase</td>
<td>No</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>*</sup> wt, wild type; TK, thymidine kinase.
arrest and/or apoptosis, depending on the cell type and severity of damage. Similar effects can be reached by ectopic expression of p53 in sensitive cells. To compare growth-suppressive properties of DU145-derived mutants with wild-type p53, we used three p53-deficient cell lines, PC3, Saos-2, and 10(1), all known to be p53-sensitive. In Saos-2 and 10(1) cells (human osteosarcoma and a variant of mouse Balb 3T3 cell lines, respectively) both alleles of the p53 gene are completely lost (5, 20). In PC3 cells (human prostate carcinoma), the only remaining allele of the p53 gene has a single nucleotide deletion in codon 138, leading to a frameshift that generates a stop codon a few nucleotides downstream of the mutation (14). The resulting aberrant protein is apparently unstable, because it cannot be detected in cell lysates (Fig. 1) even after immunoprecipitation (data not shown). Thus, PC3 cells can also be considered p53-deficient.

PC3, 10(1) and Saos-2 cells were infected with retroviral vectors expressing p53–223Leu, p53–274Phe or wild-type p53. Infection cells were selected for resistance to hygromycin and the numbers of hygro-expressing colonies were estimated. Before infection, virus titers were normalized by titration on Rat1 cells known to be resistant to ectopic expression of p53.

As shown in Fig. 1, expression of wild-type p53 was toxic for all of the cell lines tested, as judged by the inhibition of the colony growth of retrovirus-transduced cells. Surprisingly, the effects of the DU145-derived mutants were cell type-dependent. Neither p53–223Leu nor p53–274Phe affected the growth of PC3 cells, whereas the expression of both proteins was confirmed by Western immunoblotting (Fig. 1a).

Both mutants caused a growth-suppressive effect on mouse 10(1) cells, although less dramatic than wild-type p53. Consistently, cells, expanded from rare colonies, appeared after the hygromycin selection of virus-transduced 10(1) cells expressed a barely detectable level of mutated p53 protein (Fig. 1b).

Saos-2 cells showed the third pattern of sensitivity to DU145-derived mutants. p53–223Leu mutant was as active as wild-type p53 in the inhibition of colony growth of Saos-2, whereas p53–274Phe had no growth-inhibitory effect in these cells (Fig. 1c). The inhibition of colony growth in Saos-2 cells by p53–223Leu correlated with the induction of apoptosis by this mutant in a transient-transfection assay. The proapoptotic effect of the p53–223Leu mutant in these experiments was similar to that of wild-type p53, whereas transfection of p53–274Phe did not induce apoptosis (Fig. 1d).

Thus, the analysis of biological effects of p53–223Leu and p53–274Phe mutants on p53-deficient cells indicates that both of them clearly differed from wild-type p53. This difference was more pronounced in the case of p53–274Phe mutant, which showed minor growth inhibition in only one cell line and was incapable of inducing apoptosis. Another mutant, p53–223Leu, displays both of these activities in two cell lines. Remarkably, none of the mutants showed any wild-type function in human prostate PC3 cells, suggesting that some unknown tissue-specific factors might modulate p53 activity in different cell contexts.

**DU145-derived p53 Mutants Do Not Possess Dominant-Negative Activity against Wild-Type p53.** Some tumor-derived p53 mutants, acting as inhibitors of wild-type p53 (Ref. 21, and references therein), display a dominant-negative effect. We used two approaches to estimating the potential dominant-negative activity of DU145-derived mutants: (a) testing the toxicity of wild-type p53 transduced into the cells expressing the studied mutants; and (b) the suppression of p53-dependent apoptosis by transduction of the mutants.

The first type of assay was done using PC3 cells, stably expressing p53–223Leu or p53–274Phe. They were transduced with a retrovirus carrying human wild-type p53 cDNA, and the growth of virus-transduced colonies was analyzed. The results of these experi-
FUNCTIONAL COOPERATION OF p53 MUTANTS

Fig. 2. Lack of dominant-negative activity of p53–223Leu and p53–274Phe mutants against wild-type p53. a, growth of colonies of PC3-p53–223Leu, PC3-p53–274Phe, and PC3-GSE56 cells after transduction with wild-type p53. PC3-p53–223Leu, PC3-p53–274Phe, and PC3-GSE56 cells were infected with retroviruses containing empty vector (1) and wild-type p53 (2). Cells were selected in the medium with appropriate antibiotic, and the number of colonies was counted after 2 weeks and were calculated as a percentage of the number of colonies in the case of empty vector. b, C8 cells retain ability to induce p21wafl protein after transduction of the p53–223Leu and p53–274Phe mutants. Western blot analyses of p53 and p21 wafl expression in total cell lysates of C8 cells before, or 8 h after, UV treatment. c, p53–223Leu and p53–274Phe mutants do not protect C8 cells from DNA-damaging drug treatment (etoposide, doxorubicin), as opposed to control dominant-negative p53 mutants p53–175His or GSE56 (Refs. 24, 25; Fig. 2b). Thus, DU145 p53 mutants do not show dominant-negative effect against endogenous wild-type p53 in C8 cells.

p53–274Phe Can Abrogate Growth-suppressive Activity of p53–223Leu. We then tested whether p53–223Leu and p53–274Phe could affect each other’s properties if coexpressed within the same p53-deficient cells, thus imitating the situation existing in DU145 cells. p53-deficient cells were infected with the combination of two retroviruses, carrying different selectable markers, followed by the selection of cells that coexpress both constructs. Combinations used included each of the DU145-derived p53 mutants coexpressed with either the insert-free vector or with another mutant.

In PC3 cells, coexpression of both mutants did not have any detectable effect on colony growth (Fig. 1a). In 10(1) cells, previously shown to be sensitive to each mutant separately, their combination did not show any toxicity (Fig. 1b). In Saos-2 cells, which were sensitive to p53–223Leu, expression of p53–274Phe almost completely neutralized the growth suppressive effect of p53–223Leu (Fig. 1c). In transient transfection assays, coexpression of p53–274Phe with p53–223Leu resulted in ~3-fold less proportion of apoptotic cells than in the population transduced with p53–223Leu alone (Fig. 1d), indicating that the p53–274Phe mutant can abrogate the residual proapoptotic activity of p53–223Leu.

Thus, we have an interesting example of two tumor-derived p53 mutants that do not possess dominant-negative activity against wild-type p53 but are capable of neutralizing each other’s growth inhibitory activity when expressed together. This observation suggests that the DU145-derived mutants could functionally interact with each other, presumably creating p53 protein with new properties.

Conformation of DU145-derived Mutants. Biological activity of p53 largely depends on conformation of DNA-binding domain. Proper folding of DNA-binding domain of p53 can be estimated experimentally by the potency of interaction with the conformation-sensitive antibody capable of distinguishing between wild-type and mutant...
forms of the protein. We analyzed conformation of DU145-derived p53 mutants expressed in PC3 cells, separately and in combination, by immunoprecipitation with conformation-specific antibodies (Pab1620 and Pab240 recognizing preferentially wild-type and mutant p53, respectively) followed by p53 detection by biotinylated polyclonal antibodies on Western blots. As seen in Fig. 3, p53-223Leu mutant retained wild-type conformation as confirmed by its ability to bind p21 and Pab240 recognizing preferentially wild-type and mutant p53, respectively (26). Efficiency of transfection was normalized by the addition of pCMV-β-gal vector to the transfection mixture and estimation of the β-galactosidase activity in cell lysates.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4a). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4b). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4b). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4b). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4b). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4b). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.

Transactivation abilities of DU145-derived mutants were also tested in a direct transactivation assay using transient transfection of different p53-expressing constructs in combination with a CAT reporter construct driven by the promoter with p53-binding site from the p21 promoter (26). In these experiments p53-223Leu was as active as wild-type p53 in transactivation of the reporter construct, whereas p53-274Phe had no detectable activity (Fig. 4b). Coexpression of p53-274Phe inhibited transactivation by p53-223Leu, thus correlating with the above-described effects of this mutant on growth-inhibitory protein after DNA damage (Fig. 4a), suggesting that properties of the mixed p53 protein complex formed by a combination of two DU145-derived mutants may be different from the properties of the proteins formed by each of the subunits expressed separately.

Both p21waf1 and Hdm2 proteins are expressed at very low levels in PC3 cells, undetectable by Western immunoblotting. p21waf1 can be detected in PC3 expressing p53-223Leu; its expression was increased after treatment with UV light. Neither p53-274Phe nor the combination of both mutants induced p21waf1 to detectable levels (Fig. 4a). Similar results were obtained with Hdm2 expression. Detectable levels of Hdm2 were observed only in the case of PC3 expressing p53-223Leu mutant after treatment with UV (Fig. 4a), again indicating that p53-274Phe as well as the combination of mutants were incapable of visible induction of a p53-responsive gene.
activity of p53–223Leu. The lack of detectable transactivation activity of p53–274Phe suggests that the toxicity of this protein to 10(1) cells is mediated not through p21.

**DU145-derived p53 Mutants and Fas Sensitivity of PC3 Cells.** PC3 cells and DU145 cells differ dramatically in their sensitivity to Fas-mediated apoptosis (16). Whereas PC3 cells are highly sensitive, DU145 are completely resistant even to a high dose of anti-Fas antibodies. We compared the sensitivity to Fas-mediated apoptosis of parental PC3 cells and PC3 cells expressing p53–223Leu, p53–274Phe, or their combination. Fig. 5 demonstrated the dose dependence of these variants of PC3 cells to the Fas ligand agonist, anti-Fas mAb. Cell death was estimated by calcein and DNA fragmentation assays. Both methods revealed strong protection of PC3 from anti-Fas mAb-induced apoptosis by the combination of two DU145-derived mutants (results of a representative calcein assay are shown in Fig. 5). The results of cellular assays were confirmed by the analysis of caspase activation in p53 mutant-transduced PC3 cell variants (Fig. 5, bottom panel). Activated forms of caspases 8, -2, and -9 were detected in cell lysates as early as 4 h after treatment of PC3 cells, transduced with empty vectors or with p53–223Leu mutant. p53–274Phe mutant decreased the level of activated caspases, whereas a combination of both mutants prevented the appearance of activated forms of all of the studied caspases at the 4th and 8th h after adding anti-Fas mAb (Fig. 5).

Because PC3 cells that expressed each of the studied mutants separately demonstrated only partial resistance to Fas, as compared with the cells coexpressing both mutants together, we decided to check whether the effect of combined expression would be stronger than each mutant alone. We, therefore, analyzed the dependence of Fas sensitivity on the dose of mutant p53 in a transient transfection assay combined with the anti-Fas antibody treatment. In these experiments, apoptosis in transfected cells was detected by FACS analysis (proportion of cells in sub-G1 DNA fraction among transfected cells; Fig. 6). We found that both p53–223Leu and p53–274Phe induced Fas resistance in a dose-dependent manner; however, neither of them alone was as powerful in protection from apoptosis as their combination suggesting that the mutants act in an additive way.

Thus, we were able to transfer Fas-resistant phenotype of DU145 to Fas sensitive PC3 by coexpression of two DU145-derived p53 mutants. Fas resistance of DU145 cells may be overcome by treatment with cycloheximide, suggesting the involvement of a labile inhibitor (16). Interestingly, cycloheximide restored Fas sensitivity in mutant-transduced PC3 cells similarly to what it does to DU145 (Fig. 7a). This phenomenon, however, can hardly be attributed to cycloheximide-mediated reduction of the p53-mutant proteins because prolonged (up to 31 h) treatment with cycloheximide showed no dramatic changes in the levels of the mutant p53 (Fig. 7b). Thus, if Fas resistance is, in fact, mediated by some unstable protein factor, it is unlikely to be mutant p53 itself but, rather, it could be one of the proteins induced by the p53 mutants.

The most obvious mechanism of Fas resistance of tumor cells could be associated with the loss of membrane Fas. In fact, membranes of PC3 cells that were transduced with p53–274Phe contained only 27% of Fas protein as compared with cells that were transduced with empty vector, as judged by FACS analyses with anti-Fas antibodies (data not shown). To elucidate possible mechanisms of anti-Fas activity of DU145-derived p53 mutants we compared the levels of Fas protein in lysates of PC3 cells transduced with empty vector, or with constructs expressing p53–223Leu and p53–274Phe, either separately or in combination. The results shown in Fig. 8 demonstrate that p53–223Leu expression is associated with a slight decrease in the amount of Fas. The expression of p53–274Phe results in a more remarkable (~2-fold) reduction of Fas expression as compared with that in control vector-transduced PC3. The combination of both mutants has a synergistic effect on the reduction of Fas, exceeding the effect of a “double dose”
of p53–274Phe reached by coexpression of two retroviral vectors (pPS-hygro and pLPC) in the same cells.

DISCUSSION

Both alleles of the p53 gene in prostate carcinoma cells DU145 carry mutations, resulting in the coexpression of two mutant polypeptides with different amino acid substitutions (Pro to Leu in 223, and Val to Phe in 274 codons), both within the DNA-binding domain (14). None of these mutations belong to “hot spots,” although codon 274 is located between two frequently mutated codons of p53 (273 and 275). There could be several alternative explanations for the coexistence of two different p53 mutants in the same tumor: (a) each mutation results in a simple inactivation of p53 creating a phenotype that is functionally equivalent to p53 deficiency; (b) one of the mutants has a gain-of-function activity, whereas another mutation just neutralizes the other allele; and (c) there is a certain form of cooperation between the mutants creating additional selective advantages to cancer cells. To distinguish among these possibilities, we characterized the biological properties of each of the DU145-derived mutants in comparison with wild-type p53 after transduction into several p53-deficient cell lines, separately and in combination. We found that both of them are different from wild-type p53 in at least some of their properties. Although p53-274Phe has more features of a “real” cancer-derived mutant (maintains the denatured conformation of the DNA-binding domain, lacks transactivation ability) than the p53-223Leu one (wild-type conformation, transactivation ability), they both showed some properties that are unusual for tumor-derived mutants, and they more closely resemble wild-type p53 (can be stabilized by DNA damage, cause growth suppression in some cell types, do not possess dominant-negative activity). However, these relatively “weak” mutants create p53 protein with new structural and functional properties when coexpressed in one cell, p53, formed by the combination of mutants, keeps a predominantly denatured conformation, is accumulated in large amounts in the cell and does not show any increase after genotoxic stress, has no toxicity to any cells tested, and lacks transactivation function. Properties of the protein formed by the combination of mutants are clearly different from what could be expected from a simple superimposition of the individual properties of each of them. Thus, growth-suppressive activity of either of the mutants, detectable in mouse 10(1) (both mutants) and human Saos-2 cells (p53–223Leu), is completely inactivated when they are coexpressed. Synergism of the DU145-derived mutants was revealed in their effect on cell sensitivity to Fas, the most unusual property of these mutants. Whereas each of them alone had some, albeit weak, suppressive effect on the Fas sensitivity of transduced PC3 cells, the combination of p53–274Phe and p53–223Leu caused a strong anti-Fas effect presumably acting by down-regulating Fas protein expression. Transduction of the combination of 274Phe and 223Leu mutants into Fas-sensitive PC3 cells makes them resistant to Fas, as is the DU145 cell line from which these mutants are derived, suggesting that they might serve a similar function in DU145. The generation of p53 protein with new properties from a combination of two rather weak mutants and the strong inhibition of Fas-mediated apoptosis by the resulting p53 protein are two major conclusions that came out of the present work.

Inactivation of both p53 and Fas signaling are frequent events in cancer that play an important role in cancer progression. Whereas the suppression of p53 results in genomic instability and rapid progression (27), the blocking of Fas sensitivity contributes to tumor escape from host immune response (28). In addition, both may increase tumor resistance to anticancer treatment through the suppression of apoptosis (23, 29). Thus far, there have been two mechanistic links between these two pathways. In some cells, Fas behaves as a p53-responsive gene (30) and Fas sensitivity could be modulated in a p53-dependent manner after DNA-damaging treatments in vitro and in vivo (31). p53 protein was also shown to be involved in intracellular transport of Fas (32). In both cases, p53 cooperates with Fas expression. Therefore, p53 deficiency is expected to attenuate Fas-mediated apoptosis. In fact, a correlation between p53 status of the tumor and its sensitivity to Fas has been experimentally confirmed by the analysis of a series of isogenic tumor cell lines differing in their p53 status (31). Presumably, attenuation of sensitivity to Fas is one of the driving forces behind the selection of tumor cell variants with inactivated p53.

Although the inactivation of p53 may cause a reduction in cell sensitivity to Fas-induced apoptosis, it, nevertheless, cannot make the tumor cell completely Fas resistant; Fas sensitivity of p53-deficient PC3 cells (16) is an illustration for this statement. However, transduction with p53 mutants derived from Fas-resistant cells of prostate origin, DU145, converts PC3 into Fas resistance, indicating a new type of Fas-p53 interaction, in which altered p53 protein plays the role of an active inhibitor of Fas-mediated apoptosis, which causes a strong down-regulation of Fas expression. This phenomenon demonstrates a new gain-of-function activity of mutant p53.

Gain-of-function has been reported for many tumor-derived p53 mutants (5, 13, 21). Mutant p53 can acquire alterations in their transactivation capabilities (13, 33) and increase cell resistance to cytotoxic drugs even when transduced on a p53-deficient background. Down-regulation of Fas expression accompanied by resistance to Fas-mediated apoptosis is a new type of gain-of-function by p53 mutants. It is likely that mutants with such unusual properties were picked by natural selection because they provide additional selective advantages to tumor cells in vivo. Although each of the DU145-derived mutants possesses this anti-Fas property, their combined expression generates p53 protein with much stronger anti-Fas activity, providing an unusual example of gain-of-function that presumably results from the combination of two mutant p53 subunits in one protein.

Functional interaction of structurally different p53 monomers within one protein has been known for a long time as a phenomenon associated with dominant-negative mutants. It is believed that incorporation of a mutant subunit into a p53 homotetramer may result in its functional inactivation (21). In this case, one allele (inactive) clearly dominates over another one (wild-type). DU145-derived mutants, however, represent another more complicated form of functional interaction of two altered proteins. Although none of them alone showed dominant-negative activity against wild-type p53, in combination they can modify each other’s properties, presumably by creating a mixed protein complex consisting of two mutant forms of p53 protein that is not functionally equivalent to the homogeneous complexes formed by any of the subunits.

In principle, another mechanism could be responsible for the observed phenomenon. Instead of the formation of a putative “mixed” protein complex with new properties, Fas resistance may result from combined changes in gene expression caused by each of the mutants.
It this scenario, DU145-derived mutants would cooperate indirectly through their responsive genes. Although we cannot unequivocally choose between the two models, altered biochemical properties of p53 protein, resulting from the coexpression of the studied mutants, argues in favor of the first possibility.

Fas-suppressing p53 mutants can be viewed as therapeutic targets to develop compounds that would cause antitumor effect by sensitization to Fas. However, it remains unclear how common is the anti-Fas activity of tumor-derived p53 mutants; this question is the subject of our ongoing study.

ACKNOWLEDGMENTS

We thank Mary Bartos for help in manuscript preparation.

REFERENCES


Cooperation of Two Mutant $p53$ Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells

Katerina V. Gurova, Oskar W. Rokhlin, Andrei V. Budanov, et al.


**Updated version**
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/11/2905

**Cited articles**
This article cites 33 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/11/2905.full.html#ref-list-1

**Citing articles**
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
/content/63/11/2905.full.html#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.